Nimotuzumab Combined With Neoadjuvant Chemotherapy in the Treatment of Resectable LA HNSCC
Nimotuzumab Combined With Neoadjuvant Chemotherapy (TPF) in the Treatment of Resectable Locally Advanced Head and Neck Squamous Cell Carcinoma
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Anticipated)
Enrollment
Phase
Phase
- Phase 2
Contacts and Locations
Study Contact
Study Contact
- Name: Li Shi
- Phone Number: 029- 84771794
- Email: shilidoc@163.com
Study Contact Backup
- Name: Yanyan Jia
- Email: 304057101@qq.com
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- 18-80 years old, including 18 and 80 years old;
- Resectable stage III to IVa head and neck squamous cell carcinoma (including oropharyngeal carcinoma, laryngeal carcinoma and hypopharyngeal carcinoma) was confirmed by histopathology or cytology by MRI imaging;
- ECOG PS score 0-2;
- Histopathological immunohistochemical test indicated positive EGFR expression
- Histopathological immunohistochemical tests were P16 negative and EBER negative
- Lymph nodes have signs of extraperitoneal invasion (MRI, CT or pathology)
- At least one measurable lesion according to RECIST 1.1 evaluation criteria;
- Expected survival time ≥6 months;
- Hematologic indexes were basically normal: white blood cell count ≥4×109/L; Neutrophil absolute count ≥1.5×109/L; Platelet ≥100×109/L; Hemoglobin ≥90 g/L;
Normal renal function: serum creatinine ≤1.5×ULN or creatinine clearance (CrCl)> 60 mL/min(Cockcroft-Gault formula was used):
Female CrCl=(140- age)× body weight (kg)× 0.85 / (72×Scr mg/ dL) Male CrCl=(140- age)× body weight (kg)× 1.00 / (72×Scr mg/dl)
- Normal liver function: serum total bilirubin ≤1.5×ULN; Aspartate aminotransferase (AST) ≤2.5×ULN; Alanine aminotransferase (ALT) ≤2.5×ULN
- Female patients must have a negative urinary pregnancy test prior to study initiation (not available in patients with bilateral oophorectomy and/or hysterectomy or postmenopausal patients)
- Signed written informed consent.
Exclusion Criteria:
- Received PD-1 inhibitor, EGFR mab, EGFR-TKI and anti-angiogenic drugs within 4 weeks before enrollment;
- Participating in other interventional clinical trials within 30 days prior to screening;
- History of other malignant tumors (except cured basal cell carcinoma of the skin)
- there are serious and poorly controlled concurrent diseases (such as heart failure, diabetes, hypertension, liver failure, renal failure, thyroid disease, mental illness, etc.);
- known to be infected with HIV or active viral hepatitis or tuberculosis;
- Major surgical or planned surgery within 30 days of the first administration of the investigational drug;
- Allergic to drugs or ingredients used in the program;
- Women who are pregnant (as confirmed by blood or urine HCG testing) or who are lactating, or subjects of childbearing age are unwilling or unable to use effective contraceptive methods (for both male and female subjects) until at least 6 months after the last trial treatment;
- The researcher considers it inappropriate to participate in the study;
- Unwilling to participate in the study or unable to sign the informed consent.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: study arm
The study arm received nimotuzumab (400mg, every three weeks, for 2 weeks) combined with TPF chemotherapy
|
The study arm received nimotuzumab (400mg, every three weeks, for 2 weeks) combined with TPF chemotherapy
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Objective Response Rate (ORR)
Time Frame: 1 year
|
1 year
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Overall survival (OS)
Time Frame: 1 year
|
1 year
|
|
|
R0 resection rate
Time Frame: 1 year
|
1 year
|
|
|
Primary pathological complete response rate (pCR)
Time Frame: 1 year
|
1 year
|
|
|
Organ retention rate
Time Frame: 1 year
|
1 year
|
|
|
Disease free survival (DFS)
Time Frame: 1 year
|
1 year
|
|
|
Quality of life assessed by EORTC QLQ-H&N35
Time Frame: 1 year
|
Quality of life assessed by EORTC QLQ-H&N35 [EORTC QLQ-H&N35 is a specific quality of life assessment scale based on EORTC QLQ-C 30, with 35 items.
All of the scales and single-item measures range from 0 to 100.
A high score represents a higher response level.]
|
1 year
|
|
Incidence of treatment-emergent adverse events
Time Frame: 1 year
|
1 year
|
|
|
The change of tumor related markers
Time Frame: 1 year
|
The correlation of the value of EGFR, SCC-Ag, CEA and therapeutic effect [The changes of serum tumor markers (such as SCC-Ag and CEA were observed before and after treatment.
The baseline EGFR levels on the prognosis of patients should also be explored]
|
1 year
|
Collaborators and Investigators
Sponsor
Sponsor
Study record dates
Study Major Dates
Study Start (Anticipated)
Study Start
Primary Completion (Anticipated)
Primary Completion
Study Completion (Anticipated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Neoplasms by Histologic Type
- Neoplasms
- Neoplasms by Site
- Neoplasms, Glandular and Epithelial
- Head and Neck Neoplasms
- Neoplasms, Squamous Cell
- Carcinoma
- Carcinoma, Squamous Cell
- Squamous Cell Carcinoma of Head and Neck
- Molecular Mechanisms of Pharmacological Action
- Antineoplastic Agents
- Tubulin Modulators
- Antimitotic Agents
- Mitosis Modulators
- Antineoplastic Agents, Phytogenic
- Antineoplastic Agents, Immunological
- Paclitaxel
- Nimotuzumab
- Nedaplatin
Other Study ID Numbers
Other Study ID Numbers
- BPL-Nim-20210407
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.